Kadimastem Ltd (KMSTF)
USD 0.64
(-90.0%)
USD 0.64
(-90.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -253.1 Thousand USD | 62.92% |
| 2022 | -682.57 Thousand USD | 89.66% |
| 2021 | -6.6 Million USD | -381.45% |
| 2020 | 2.34 Million USD | -16.82% |
| 2019 | 2.81 Million USD | 199.62% |
| 2018 | -2.83 Million ILS | -26.94% |
| 2017 | -2.23 Million ILS | -290.39% |
| 2016 | 1.17 Million ILS | 260.41% |
| 2015 | 325 Thousand ILS | -89.34% |
| 2014 | 3.04 Million ILS | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | -220.21 Thousand USD | 0.0% |
| 2023 Q4 | -253.1 Thousand USD | 0.0% |
| 2023 FY | -253.1 Thousand USD | 62.92% |
| 2022 FY | -682.57 Thousand USD | 89.66% |
| 2022 Q2 | -2.88 Million ILS | 0.0% |
| 2022 Q4 | -682.57 Thousand USD | 0.0% |
| 2021 Q2 | 54.62 Thousand ILS | 0.0% |
| 2021 FY | -6.6 Million USD | -381.45% |
| 2021 Q4 | -6.6 Million ILS | 0.0% |
| 2020 FY | 2.34 Million USD | -16.82% |
| 2020 Q1 | 8.26 Million ILS | 192.92% |
| 2020 Q2 | 2.61 Million ILS | -68.3% |
| 2020 Q4 | 2.34 Million USD | 0.0% |
| 2019 FY | 2.81 Million USD | 199.62% |
| 2019 Q4 | 2.81 Million ILS | 0.0% |
| 2019 Q2 | -419.17 Thousand ILS | 0.0% |
| 2018 FY | -2.83 Million ILS | -26.94% |
| 2018 Q4 | -11.1 Million ILS | 0.0% |
| 2018 Q2 | -1.59 Million ILS | 0.0% |
| 2017 FY | -2.23 Million ILS | -290.39% |
| 2017 Q4 | -8.77 Million ILS | 0.0% |
| 2017 Q2 | 1.21 Million ILS | 0.0% |
| 2016 FY | 1.17 Million ILS | 260.41% |
| 2016 Q4 | 3.47 Million ILS | 0.0% |
| 2015 FY | 325 Thousand ILS | -89.34% |
| 2014 FY | 3.04 Million ILS | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -19220.763% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 104.481% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.591% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -1.395% |
| Rebus Holdings, Inc. | 305 Thousand USD | 182.984% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 95.985% |
| Qrons Inc. | 351.42 Thousand USD | 172.021% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 140.668% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.583% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -1140.21% |
| Skye Bioscience, Inc. | -5.72 Million USD | 95.576% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 101.606% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 106.146% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 162.984% |
| SQZ Biotechnologies Company | -36.23 Million USD | 99.302% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 111.288% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 127.298% |
| Mesoblast Limited | 55.85 Million USD | 100.453% |
| Marizyme, Inc. | 18.56 Million USD | 101.363% |
| Genus plc | 190.6 Million USD | 100.133% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 111.32% |
| Pharming Group N.V. | 109.8 Million USD | 100.231% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 129.422% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 120.851% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 137.221% |
| ContraFect Corporation | -6.02 Million USD | 95.8% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 287.986% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 121.905% |
| IMV Inc. | 7.67 Million USD | 103.3% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 104.6% |
| MultiCell Technologies, Inc. | 90.04 USD | 281199.511% |
| ONE Bio Corp. | 9.04 Million USD | 102.8% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 65.516% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 101.955% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 118.502% |
| Q BioMed Inc. | 4.06 Million USD | 106.234% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.828% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 125.116% |
| Biomind Labs Inc. | 711.4 Thousand USD | 135.578% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.418% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 112.659% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 101.976% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 170.363% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 281.041% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 1373.982% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 111.494% |
| GB Sciences, Inc. | 1.74 Million USD | 114.485% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -37.714% |
| HST Global, Inc. | 96.79 Thousand USD | 361.488% |
| CSL Limited | 10.52 Billion USD | 100.002% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 222.736% |
| Halberd Corporation | 144.72 Thousand USD | 274.89% |
| Enzolytics Inc. | 981.65 Thousand USD | 125.783% |
| Agentix Corp. | 37.63 Thousand USD | 772.589% |
| Resverlogix Corp. | 6.45 Million USD | 103.923% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 62.397% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.988% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.462% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 103.579% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 109.344% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 97.137% |
| AVAX Technologies, Inc. | -5.9 Million USD | 95.712% |
| Zenith Capital Corp. | 10.06 Thousand USD | 2614.924% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.976% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 226.278% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 110.608% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 253.853% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -1281.712% |
| Helix BioMedix, Inc. | -2.57 Million USD | 90.152% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 101.248% |
| BioStem Technologies, Inc. | 4.47 Million USD | 105.66% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 225.762% |
| LadRx Corporation | -2.03 Million USD | 87.572% |
| Cell Source, Inc. | 9.23 Million USD | 102.742% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 139.848% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 139.848% |
| NovAccess Global Inc. | 2.17 Million USD | 111.618% |
| Affymax, Inc. | -5.59 Million USD | 95.478% |
| Itoco Inc. | 228.3 Thousand USD | 210.861% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 286.119% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 105.106% |
| Mobile Lads Corp. | 484.23 Thousand USD | 152.269% |
| CytoDyn Inc. | 20.26 Million USD | 101.249% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -39019.32% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -2630.823% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 103.284% |
| SYBLEU INC | 473.71 Thousand USD | 153.429% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 105.679% |
| International Stem Cell Corporation | 2.59 Million USD | 109.772% |
| Bioxytran, Inc. | 1.89 Million USD | 113.329% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 505.528% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 111.605% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 107.37% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 102.959% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 132.759% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 79.752% |
| Neutra Corp. | 52.18 Thousand USD | 584.991% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 89.831% |
| PureTech Health plc | -167.19 Million USD | 99.849% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -3.346% |
| IXICO plc | -4.44 Million USD | 94.305% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 101.915% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.461% |
| CSL Limited | 10.52 Billion USD | 100.002% |
| Cellectis S.A. | -43.81 Million USD | 99.422% |